Breast Cancer Clinical Trial
Official title:
Phase I/II Study of High-Dose Megestrol in Breast or Endometrial Carcinoma or Mesothelioma
RATIONALE: Some hormones can stimulate the growth of some types of cancer cells. Hormone
therapy using megestrol may fight cancer by reducing the production of these hormones.
PURPOSE: Phase I/II trial to study the effectiveness of high-dose megestrol in treating
patients with metastatic breast cancer, endometrial cancer, or mesothelioma which cannot be
treated with surgery or radiation therapy.
OBJECTIVES: I. Evaluate the clinical effects of high-dose oral megestrol in improving
regression rate and prolonging survival in patients with breast or endometrial carcinoma or
mesothelioma. II. Evaluate the immune, endocrine, and clinical effects of this regimen, with
particular attention to effects on cachexia.
OUTLINE: This is a randomized study. Patients are stratified by performance status, dominant
site of disease, and prior treatment with megestrol. Breast cancer patients are randomized
to one of 3 doses of oral megestrol (800, 1,280, or 1,600 mg/day, divided qid). Female
patients with other tumor types are nonrandomly assigned to receive oral megestrol at 1,600
mg/day. Male patients are nonrandomly assigned to a dose-finding study of megestrol. The
first patient cohort receives megestrol at 480 mg/day in 3 divided doses, with further
escalation for subsequent cohorts as tolerated. All patients continue therapy for at least 8
weeks, with treatment discontinued upon progression. Measurable lesions are evaluated every
2 months.
PROJECTED ACCRUAL: 9 evaluable breast cancer patients at each dose level will be entered; 14
patients will be required for each of the other disease categories. (As of 11/92, the study
is temporarily closed to patients with prostate cancer.)
;
Primary Purpose: Treatment
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Recruiting |
NCT04681911 -
Inetetamab Combined With Pyrotinib and Chemotherapy in the Treatment of HER2 Positive Metastatic Breast Cancer
|
Phase 2 | |
| Terminated |
NCT04066790 -
Pyrotinib or Trastuzumab Plus Nab-paclitaxel as Neoadjuvant Therapy in HER2-positive Breast Cancer
|
Phase 2 | |
| Completed |
NCT04890327 -
Web-based Family History Tool
|
N/A | |
| Completed |
NCT03591848 -
Pilot Study of a Web-based Decision Aid for Young Women With Breast Cancer, During the Proposal for Preservation of Fertility
|
N/A | |
| Recruiting |
NCT03954197 -
Evaluation of Priming Before in Vitro Maturation for Fertility Preservation in Breast Cancer Patients
|
N/A | |
| Terminated |
NCT02202746 -
A Study to Assess the Safety and Efficacy of the VEGFR-FGFR-PDGFR Inhibitor, Lucitanib, Given to Patients With Metastatic Breast Cancer
|
Phase 2 | |
| Active, not recruiting |
NCT01472094 -
The Hurria Older PatiEnts (HOPE) With Breast Cancer Study
|
||
| Completed |
NCT06049446 -
Combining CEM and Magnetic Seed Localization of Non-Palpable Breast Tumors
|
||
| Withdrawn |
NCT06057636 -
Hypnosis for Pain in Black Women With Advanced Breast Cancer: A Feasibility Study
|
N/A | |
| Recruiting |
NCT05560334 -
A Single-Arm, Open, Exploratory Clinical Study of Pemigatinib in the Treatment of HER2-negative Advanced Breast Cancer Patients With FGFR Alterations
|
Phase 2 | |
| Active, not recruiting |
NCT05501769 -
ARV-471 in Combination With Everolimus for the Treatment of Advanced or Metastatic ER+, HER2- Breast Cancer
|
Phase 1 | |
| Recruiting |
NCT04631835 -
Phase I Study of the HS-10352 in Patients With Advanced Breast Cancer
|
Phase 1 | |
| Completed |
NCT04307407 -
Exercise in Breast Cancer Survivors
|
N/A | |
| Recruiting |
NCT03544762 -
Correlation of 16α-[18F]Fluoro-17β-estradiol PET Imaging With ESR1 Mutation
|
Phase 3 | |
| Terminated |
NCT02482389 -
Study of Preoperative Boost Radiotherapy
|
N/A | |
| Enrolling by invitation |
NCT00068003 -
Harvesting Cells for Experimental Cancer Treatments
|
||
| Completed |
NCT00226967 -
Stress, Diurnal Cortisol, and Breast Cancer Survival
|
||
| Recruiting |
NCT06037954 -
A Study of Mental Health Care in People With Cancer
|
N/A | |
| Recruiting |
NCT06019325 -
Rhomboid Intercostal Plane Block on Chronic Pain Incidence and Acute Pain Scores After Mastectomy
|
N/A | |
| Recruiting |
NCT06006390 -
CEA Targeting Chimeric Antigen Receptor T Lymphocytes (CAR-T) in the Treatment of CEA Positive Advanced Solid Tumors
|
Phase 1/Phase 2 |